Shorter blood thinner course after birth may be just as safe
NCT ID NCT05058924
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested whether a shorter course of blood thinner (LMWH) followed by aspirin is as good as the standard 6 weeks of LMWH for preventing blood clots after childbirth. The study enrolled 30 women at moderate to high risk of clots. The main goal was to see if women would agree to join and stick with the treatment, not to measure clot prevention directly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Low molecular weight heparin (LMWH) and low-dose aspirin
- What this could lead to
- If successful, this could point to a shorter, more convenient way to prevent dangerous blood clots after childbirth, reducing the need for daily injections.
- What could go wrong
- This is a very small pilot study with only 30 participants, so results may not apply to everyone. The study focuses on feasibility, not on proving the treatment works better.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENOUS THROMBOEMBOLISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mount Sinai Hospital
Toronto, Ontario, M5G 1Z5, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could tailored blood thinner dosing prevent strokes in chinese patients?
- Could a simple aspirin pill replace daily shots to prevent postpartum blood clots?
- Simple 5-Step nursing plan could slash deadly clot risk after hip surgery
- Timing of blood thinners after childbirth bleeding may prevent clots without causing more harm
- New scan may predict dangerous clot return in lung patients
- Massive study tests if insurance records can mimic Gold-Standard drug trials